Biomerica reports real-world IBS test results, Medicare rate set
#Biomerica #inFoods IBS test #real-world study #Medicare rate #abdominal pain #bloating #diagnostic testing #healthcare
📌 Key Takeaways
- Biomerica reported real-world study results for its inFoods IBS test
- 59.4% of patients achieved at least 30% reduction in abdominal pain
- 68.1% achieved similar reduction in bloating symptoms
- The company has established a Medicare rate for the test
📖 Full Retelling
Biomerica Inc. (NASDAQ:BMRA) announced results from a real-world study of its inFoods IBS test in Irvine, California on Thursday, revealing significant improvements in patient symptoms including abdominal pain and bloating. According to the company's statement, the study demonstrated that 59.4% of patients achieved at least a 30% reduction in abdominal pain, while 68.1% experienced a similar reduction in bloating symptoms. These findings highlight the potential effectiveness of Biomerica's inFoods IBS test in managing common irritable bowel syndrome symptoms that affect millions of Americans. The announcement comes as Biomerica has also established a Medicare rate for the inFoods IBS test, which could significantly impact patient accessibility and insurance coverage for this diagnostic tool.
🏷️ Themes
Medical innovation, Healthcare economics, Diagnostic testing
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
IRVINE, Calif. - Biomerica Inc. (NASDAQ:BMRA) reported results from a real-world study of its inFoods IBS test showing 59.4% of patients achieved at least 30% reduction in abdominal pain and 68.1% achieved similar reduction in bloating, according to a press release statement issued Thursday.
Read full article at source